Lymphokine gene therapy for cancer

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The plethora of recombinant lymphokines that have recently become available has led to renewed hope for an immunotherapeutic solution to cancer. Many lymphokines, either singly or in combination, have already shown promise in animal trials and in preliminary human trials. Systemic lymphokine toxicity has been the major constraint on this type of therapy, often precluding the use of doses sufficient to induce tumour regression. To realize the therapeutic potential of recombinant lymphokines against cancer, alternative modes of delivery are needed which maximally stimulate local anti-tumour responses whilst causing minimal systemic toxicity. In this article, Stephen Russell proposes that tumour cell targeted lymphokine gene therapy would optimize lymphokine delivery. Some of the practical difficulties likely to be encountered with such an approach are also discussed.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
JournalImmunology Today
Volume11
Issue numberC
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Lymphokines
Genetic Therapy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Lymphokine gene therapy for cancer. / Russell, Stephen J.

In: Immunology Today, Vol. 11, No. C, 1990, p. 196-200.

Research output: Contribution to journalArticle

Russell, Stephen J. / Lymphokine gene therapy for cancer. In: Immunology Today. 1990 ; Vol. 11, No. C. pp. 196-200.
@article{6aeb2898cb0349ae84509ca11d2a2cc6,
title = "Lymphokine gene therapy for cancer",
abstract = "The plethora of recombinant lymphokines that have recently become available has led to renewed hope for an immunotherapeutic solution to cancer. Many lymphokines, either singly or in combination, have already shown promise in animal trials and in preliminary human trials. Systemic lymphokine toxicity has been the major constraint on this type of therapy, often precluding the use of doses sufficient to induce tumour regression. To realize the therapeutic potential of recombinant lymphokines against cancer, alternative modes of delivery are needed which maximally stimulate local anti-tumour responses whilst causing minimal systemic toxicity. In this article, Stephen Russell proposes that tumour cell targeted lymphokine gene therapy would optimize lymphokine delivery. Some of the practical difficulties likely to be encountered with such an approach are also discussed.",
author = "Russell, {Stephen J}",
year = "1990",
doi = "10.1016/0167-5699(90)90081-J",
language = "English (US)",
volume = "11",
pages = "196--200",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "C",

}

TY - JOUR

T1 - Lymphokine gene therapy for cancer

AU - Russell, Stephen J

PY - 1990

Y1 - 1990

N2 - The plethora of recombinant lymphokines that have recently become available has led to renewed hope for an immunotherapeutic solution to cancer. Many lymphokines, either singly or in combination, have already shown promise in animal trials and in preliminary human trials. Systemic lymphokine toxicity has been the major constraint on this type of therapy, often precluding the use of doses sufficient to induce tumour regression. To realize the therapeutic potential of recombinant lymphokines against cancer, alternative modes of delivery are needed which maximally stimulate local anti-tumour responses whilst causing minimal systemic toxicity. In this article, Stephen Russell proposes that tumour cell targeted lymphokine gene therapy would optimize lymphokine delivery. Some of the practical difficulties likely to be encountered with such an approach are also discussed.

AB - The plethora of recombinant lymphokines that have recently become available has led to renewed hope for an immunotherapeutic solution to cancer. Many lymphokines, either singly or in combination, have already shown promise in animal trials and in preliminary human trials. Systemic lymphokine toxicity has been the major constraint on this type of therapy, often precluding the use of doses sufficient to induce tumour regression. To realize the therapeutic potential of recombinant lymphokines against cancer, alternative modes of delivery are needed which maximally stimulate local anti-tumour responses whilst causing minimal systemic toxicity. In this article, Stephen Russell proposes that tumour cell targeted lymphokine gene therapy would optimize lymphokine delivery. Some of the practical difficulties likely to be encountered with such an approach are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0025315922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025315922&partnerID=8YFLogxK

U2 - 10.1016/0167-5699(90)90081-J

DO - 10.1016/0167-5699(90)90081-J

M3 - Article

C2 - 2191681

AN - SCOPUS:0025315922

VL - 11

SP - 196

EP - 200

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - C

ER -